Phase 2 study of avacopan for treatment of C3G, IND 132321, orphan designation 16-5590
Ended Project Grant Awarded Last action
- Award ID
- R01FD006342
- Recipient
-
Chemocentryx, Inc. UEI EVYLGAKQEUL8
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,000,000
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $500,000 | |
| Original award | $500,000 |
Quick answers
Who received award R01FD006342?
R01FD006342 was awarded to Chemocentryx, Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 10, 2019.
How much is award R01FD006342 worth?
$1,000,000 has been obligated on R01FD006342.
Which agency awarded R01FD006342?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD006342, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award